Clinical Trials Logo
  1. Home
  2. Age-Related Macular Degeneration
  3. NCT01644513

Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients — EVERGREEN  

Age Related Macular Degeneration Clinical Trial

Official title:
Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal Anti-VEGF Injections (Bevacizumab or Ranibizumab) to Evaluate the Association Between Genetic Load and Response to Therapy/Treatment Burden

Clinical Trial Summary

Patients with AMD who are being or have been treated with eye injections of drugs known as anti-VEGF agents with either good or poor response will have DNA collected with check swabs for analysis.

Clinical Trial Description

The study is designed as a single-center, observational case control evaluation to compare the genetic profiles of two groups of patients categorized according to anti-VEGF treatment response as either "positive" or "suboptimal" responders following treatment with either bevacizumab or ranibizumab anti-VEGF agents. Positive and suboptimal responders will be compared to determine if genetic variant distribution or total genetic load is associated with anti-VEGF treatment response. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01644513
Study type Observational
Source Sequenom, Inc.
Contact
Status Completed
Phase N/A
Start date July 2012
Completion date December 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03963817 - Snapshot Camera for AMD
Recruiting NCT04929756 - Eye Movement Rehabilitation in Low Vision Patients
Completed NCT04779398 - Association of MPOD Values With Blue Light.
Terminated NCT03275753 - Visual Function Tests in Age-related Macular Degeneration
Recruiting NCT03609307 - Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial Phase 2/Phase 3
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Completed NCT02556723 - Intravitreal Injections of Ziv-aflibercept for Macular Diseases N/A
Active, not recruiting NCT01943396 - Treatment of AMD With Rheohemapheresis /RHF/ Phase 4
Completed NCT00963339 - Age-Related Macular Degeneration (AMD) - Usability Study N/A
Completed NCT00376701 - Combination Therapy for Age-Related Macular Degeneration. Phase 2
Terminated NCT00347165 - Intravitreal Bevacizumab for Age-Related Macular Degeneration Phase 2
Completed NCT00800995 - Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD) Phase 3
Completed NCT04689789 - OCTA and Retinal Angiomatous Proliferation
Completed NCT02567604 - Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
Completed NCT02173496 - Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
Recruiting NCT01991730 - Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients N/A
Active, not recruiting NCT01657669 - Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results Phase 4
Completed NCT00776763 - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab Phase 2
Completed NCT00791570 - Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy Phase 1
Completed NCT00413829 - Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB) Phase 2